Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial
Open Access
- 13 November 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 24 (6) , 910-920
Abstract
The Routine vs. Aggressive risk factor driven upstream rhythm Control for prevention of Early persistent atrial fibrillation (AF) in heart failure (HF) (RACE 3) trial demonstrated that targeted therapy of underlying conditions improved sinus rhythm maintenance at 1 year. We now explored the effects of targeted therapy on the additional co-primary endpoints; sinus rhythm maintenance and cardiovascular outcome at 5 years. Patients with early persistent AF and mild-to-moderate stable HF were randomized to targeted or conventional therapy. Both groups received rhythm control therapy according to guidelines. The targeted group additionally received four therapies: angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers (ARBs), statins, mineralocorticoid receptor antagonists (MRAs), and cardiac rehabilitation. The presence of sinus rhythm and cardiovascular morbidity and mortality at 5-year follow-up were assessed. Two hundred and sixteen patients consented for long-term follow-up, 107 were randomized to targeted and 109 to conventional therapy. At 5 years, MRAs [76 (74%) vs. 10 (9%) patients, P < 0.001] and statins [81 (79%) vs. 59 (55%), P < 0.001] were used more in the targeted than conventional group. Angiotensin-converting enzyme inhibitors/ARBs and physical activity were not different between groups. Sinus rhythm was present in 49 (46%) targeted vs. 43 (39%) conventional group patients at 5 years (odds ratio 1.297, lower limit of 95% confidence interval 0.756, P = 0.346). Cardiovascular mortality and morbidity occurred in 20 (19%) in the targeted and 15 (14%) conventional group patients, P = 0.353. In patients with early persistent AF and HF superiority of targeted therapy in sinus rhythm maintenance could not be preserved at 5-year follow-up. Cardiovascular outcome was not different between groups. Clinicaltrials.gov NCT00877643.Keywords
Funding Information
- Netherlands Heart Foundation (2008B035)
- AstraZeneca
- Bayer
- Biotronik
- Boston Scientific
- Medtronic
- Sanofi-Aventis
This publication has 19 references indexed in Scilit:
- Catheter Ablation for Atrial Fibrillation with Heart FailureNew England Journal of Medicine, 2018
- Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trialEuropean Heart Journal, 2018
- The influence of progression of atrial fibrillation on quality of life: a report from the Euro Heart SurveyEP Europace, 2017
- Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter AblationCirculation, 2017
- Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AFEuropean Heart Journal, 2016
- Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular DiseaseNew England Journal of Medicine, 2016
- The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysisEuropean Heart Journal, 2016
- Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 studyNetherlands Heart Journal, 2013
- Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary preventionEP Europace, 2011
- Differential effects of high-frequency versus low-frequency exercise training in rehabilitation of patients with coronary artery diseaseJACC, 2000